|Healthcare Review: Sirona Dental Systems, Rosetta Genomics, Optimer Pharmaceuticals, Repros Therapeutics, Progenics Pharmaceuticals|
|By Staff and Wire Reports|
|Friday, 10 May 2013 13:35|
Following are notable movers at mid day on Friday:
Sirona Dental Systems, Inc. (NASDAQ:SIRO) shares declined 5.85% to $71 in the morning hour. The company on May 10 said its fiscal second-quarter net income rose 4 percent, helped by strong demand for its imaging and computer-aided design and computer-aided manufacturing products. For the quarter ended March 31, the company earned $31.7 million, or 56 cents per share, up from $30.5 million, or 54 cents per share, a year earlier. Adjusted profit was 75 cents per share for the recent quarter. Revenue rose 15 percent to $267.3 million from $231.9 million. Analysts, on average, expected a profit of 72 cents per share on $255.7 million in revenue, according to FactSet.
Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) stock jumped 2.13% to $3.35. The company on May 10 announces receipt of $625,000as payment in full from the negotiated settlement announced on April 18, 2013with Sanra Laboratories (Sanra) in connection with the Company's sale to Sanra of Parkway Clinical Laboratories (Parkway).
Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) shares fell 16.49% to $12.46. The company on May 9 announced unaudited financial results for the first quarter ended March 31, 2013. Total net revenues for the quarters ended March 31, 2013 and 2012 were $19.4 million and $14.4 million, respectively, an increase of $5.0 million. Net loss for the first quarter of 2013 was $31.3 million, or $0.65 cents per share, on a basic and diluted basis, as compared to net loss for the first quarter of 2012 of $10.9 million, or $0.23 cents per share, on a basic and diluted basis.
Repros Therapeutics Inc. (NASDAQ:RPRX) stock gained 0.24% to $18.32. The company, on April 29, announced it is collaborating with Feinberg School of Medicine and the Breast Cancer Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in the conduct of a physician sponsored IND investigating the potential for the use of Proellex® in the treatment of breast cancer in a window-of-opportunity design.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) shares increased 0.93% to $4.34. The company on May 10 announced its results of operations for the quarter ended March 31. Net loss for the quarter was $11.3 million or $0.22 diluted per share, compared to net loss of $13.1 million or $0.39 diluted per share in the 2012 period, due primarily to a $1.8 million decrease in total expenses. The company ended the quarter with cash, cash equivalents and securities of $58.4 million, reflecting use of $3.6 million for operations in the quarter. First quarter revenue totaled $2.2 million for the current and prior-year periods.